Twitter Facebook LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Pelican Therapeutics
  • Technology
    • gp96 Platform
    • Pelican’s PTX-35 Co-stimulatory Antibody
  • Product Pipeline
    • Overview
    • HS-110
    • HS-130
    • COVID-19 Vaccine
    • PTX-35
    • Expanded Access
    • Scientific Publications
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • Corporate Presentation
  • News & Media
    • News Releases
    • Events
  • Careers
  • Contact

News Releases

News & Media

News & Media

  • News Releases
  • Events

Heat Biologics Announces Completion of ZVX-60 Vaccine Cell Line for COVID-19

Dec 16, 2020

Heat Biologics Provides Business Update

Dec 10, 2020

Heat Biologics Provides Third Quarter 2020 Business Update

Nov 9, 2020

Heat Biologics Issued Additional Patent on gp96 Combination Platform Therapy with T-cell Co-Stimulator

Oct 7, 2020

Heat Biologics CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th

Sep 9, 2020

Heat Biologics Issued Key Patent on Combination Platform Therapy

Sep 2, 2020

Heat Biologics Announces Publication of Preclinical COVID-19 Vaccine Results

Aug 26, 2020

Heat Biologic's COVID-19 Vaccine Demonstrates Robust T Cell Driven Immune Response to SARS-CoV-2 in Preclinical Studies

Aug 13, 2020

Heat Biologics Provides Second Quarter 2020 Business Update

Aug 7, 2020

Heat Biologics Highlights Importance of T cell Immunity to Prevent COVID-19

Aug 5, 2020
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...25
    © 2021 Heat Biologics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap LinkedIn